An observational study in Rheumatoid Arthritis (RA) and Lung Neoplasms, sponsored by University Hospital, Limoges. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by University Hospital, Limoges · Observational
Patients with rheumatoid arthritis (RA) have an increased risk of lung cancer, potentially influenced by targeted therapies such as JAK inhibitors and biologics. Extracellular vesicles (EVs) are key mediators of intercellular communication and may carry biomarkers involved in oncogenesis. This study aims to compare EV concentration and molecular content in RA patients treated with different targeted therapies. The objective is to identify treatment-related differences in EV profiles that may contribute to lung cancer development and improve risk stratification.
RA is associated with an increased incidence of lung cancer, with recent evidence suggesting a differential risk according to targeted therapies. The biological mechanisms underlying this association remain unclear. EVs are circulating nanovesicles involved in immune regulation and tumor progression, carrying proteins and nucleic acids that may reflect disease and treatment effects. This prospective monocentric observational study will include RA patients treated with JAK inhibitors, abatacept, anti-TNF, or anti-IL-6 therapies. A single additional blood sample will be collected during routine care. EV concentration will be measured, and their protein and miRNA content analyzed using omics approaches. Functional assays will assess the impact of EVs on bronchial epithelial and lung cancer cell lines.The study aims to identify EV-based biomarkers associated with specific treatments and potentially linked to lung cancer risk.
2,971 studies on the registry are indexed under Arthritis, Rheumatoid; 399 are open to participants now.
This study's planned enrollment of 136 is below the median of 176 across 856 observational studies indexed under Arthritis, Rheumatoid.
Browse Arthritis, Rheumatoid studies →University Hospital, Limoges is the lead sponsor of 264 studies on the registry; 38 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients receiving rheumatology care at Limoges University Hospital with diagnosis of RA established
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Collection of additional blood tubes during a routine blood test
Plasma extracellular vesicle (EV) concentration at inclusion
Extracellular vesicle concentration will be measured, and their protein and miRNA content analyzed using omics approaches. Functional assays will assess the impact of EVs on bronchial epithelial and lung cancer cell lines.The study aims to identify EV-based biomarkers associated with specific treatments and potentially linked to lung cancer risk.
Time frame: 6 months
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Limoges →